MDxHealth Gross Margin

What does MDxHealth do? MDxHealth SA generates revenue through its molecular diagnostic tests for cancer care, including ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma, and AssureMDx for Bladder Cancer. The company serves healthcare providers and physicians who use these tests to personalize cancer diagnosis and treatment decisions. Its proprietary technologies focus on genetic, epigenetic (methylation), and molecular analysis to assist in urologic cancer diagnosis, recurrence risk assessment, and therapy response prediction. The firm operates laboratories in Nijmegen, Netherlands, and Irvine, United States, supporting its diagnostic services. The company's primary customers are physicians and healthcare institutions seeking actionable diagnostic information for cancer patients. These tests help in determining the best treatment pathways, reducing unnecessary procedures, and improving patient outcomes. MDxHealth SA's business model relies on selling these diagnostic services directly to medical professionals and institutions across multiple regions. MDxHealth SA's revenue streams are derived from the sale of its proprietary diagnostic tests, which are based on advanced molecular technologies. The tests target specific cancer types, such as prostate, bladder, and glioblastoma cancers, with each test offering unique diagnostic capabilities. The company's laboratory operations in Nijmegen and Irvine enable efficient test processing and delivery to clients. MDxHealth is one of the most popular companies on Eulerpool.